Literature DB >> 22982598

Glutathione redox cycle dysregulation in Huntington's disease knock-in striatal cells.

Márcio Ribeiro1, Tatiana R Rosenstock, Teresa Cunha-Oliveira, Ildete L Ferreira, Catarina R Oliveira, A Cristina Rego.   

Abstract

Huntington's disease (HD) is a CAG repeat disorder affecting the HD gene, which encodes for huntingtin (Htt) and is characterized by prominent cell death in the striatum. Oxidative stress was previously implicated in HD neurodegeneration, but the role of the major endogenous antioxidant system, the glutathione redox cycle, has been less studied following expression of full-length mutant Htt (FL-mHtt). Thus, in this work we analyzed the glutathione system in striatal cells derived from HD knock-in mice expressing mutant Htt versus wild-type cells. Mutant cells showed increased intracellular reactive oxygen species (ROS) and caspase-3 activity, which were significantly prevented following treatment with glutathione ethyl ester. Interestingly, mutant cells exhibited an increase in intracellular levels of both reduced and oxidized forms of glutathione, and enhanced activities of glutathione peroxidase (GPx) and glutathione reductase (GRed). Furthermore, glutathione-S-transferase (GST) and γ-glutamyl transpeptidase (γ-GT) activities were also increased in mutant cells. Nevertheless, glutamate-cysteine ligase (GCL) and glutathione synthetase (GS) activities and levels of GCL catalytic subunit were decreased in cells expressing FL-mHtt, highly suggesting decreased de novo synthesis of glutathione. Enhanced intracellular total glutathione, despite decreased synthesis, could be explained by decreased extracellular glutathione in mutant cells. This occurred concomitantly with decreased mRNA expression levels and activity of the multidrug resistance protein 1 (Mrp1), a transport protein that mediates cellular export of glutathione disulfide and glutathione conjugates. Additionally, inhibition of Mrp1 enhanced intracellular GSH in wild-type cells only. These data suggest that FL-mHtt affects the export of glutathione by decreasing the expression of Mrp1. Data further suggest that boosting of GSH-related antioxidant defense mechanisms induced by FL-mHtt is insufficient to counterbalance increased ROS formation and emergent apoptotic features in HD striatal cells.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22982598     DOI: 10.1016/j.freeradbiomed.2012.09.004

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  21 in total

1.  Activation of IGF-1 and insulin signaling pathways ameliorate mitochondrial function and energy metabolism in Huntington's Disease human lymphoblasts.

Authors:  Luana Naia; I Luísa Ferreira; Teresa Cunha-Oliveira; Ana I Duarte; Márcio Ribeiro; Tatiana R Rosenstock; Mário N Laço; Maria J Ribeiro; Catarina R Oliveira; Frédéric Saudou; Sandrine Humbert; A Cristina Rego
Journal:  Mol Neurobiol       Date:  2014-05-20       Impact factor: 5.590

2.  Dysregulation of system xc(-) expression induced by mutant huntingtin in a striatal neuronal cell line and in R6/2 mice.

Authors:  Natalie M Frederick; Julie Bertho; Kishan K Patel; Geraldine T Petr; Ekaterina Bakradze; Sylvia B Smith; Paul A Rosenberg
Journal:  Neurochem Int       Date:  2014-07-05       Impact factor: 3.921

3.  Bezafibrate In Vivo Administration Prevents 3-Methylglutaric Acid-Induced Impairment of Redox Status, Mitochondrial Biogenesis, and Neural Injury in Brain of Developing Rats.

Authors:  Nevton Teixeira da Rosa-Junior; Belisa Parmeggiani; Mateus Struecker da Rosa; Nícolas Manzke Glänzel; Leonardo de Moura Alvorcem; Moacir Wajner; Guilhian Leipnitz
Journal:  Neurotox Res       Date:  2019-03-09       Impact factor: 3.911

4.  Oxygen Consumption Evaluation: An Important Indicator of Metabolic State, Cellular Function, and Cell Fate Along Neural Deregulation.

Authors:  Mariana Dutra Brito; Luiz Felipe Souza E Silva; Amanda Siena; Miruna Chipara; Sovan Sarkar; Tatiana Rosado Rosenstock
Journal:  Methods Mol Biol       Date:  2021

5.  Increased TRPC5 glutathionylation contributes to striatal neuron loss in Huntington's disease.

Authors:  Chansik Hong; Hyemyung Seo; Misun Kwak; Jeha Jeon; Jihoon Jang; Eui Man Jeong; Jongyun Myeong; Yu Jin Hwang; Kotdaji Ha; Min Jueng Kang; Kyu Pil Lee; Eugene C Yi; In-Gyu Kim; Ju-Hong Jeon; Hoon Ryu; Insuk So
Journal:  Brain       Date:  2015-06-30       Impact factor: 13.501

6.  Histone Deacetylase Inhibitors Protect Against Pyruvate Dehydrogenase Dysfunction in Huntington's Disease.

Authors:  Luana Naia; Teresa Cunha-Oliveira; Joana Rodrigues; Tatiana R Rosenstock; Ana Oliveira; Márcio Ribeiro; Catarina Carmo; Sofia I Oliveira-Sousa; Ana I Duarte; Michael R Hayden; A Cristina Rego
Journal:  J Neurosci       Date:  2017-01-25       Impact factor: 6.167

Review 7.  Main path and byways: non-vesicular glutamate release by system xc(-) as an important modifier of glutamatergic neurotransmission.

Authors:  Ann Massie; Séverine Boillée; Sandra Hewett; Lori Knackstedt; Jan Lewerenz
Journal:  J Neurochem       Date:  2015-09-29       Impact factor: 5.372

8.  Conditional Human Immunodeficiency Virus Transactivator of Transcription Protein Expression Induces Depression-like Effects and Oxidative Stress.

Authors:  Jay P McLaughlin; Jason J Paris; Dionyssios Mintzopoulos; Kristen A Hymel; Jae K Kim; Thomas J Cirino; Timothy E Gillis; Shainnel O Eans; Gordana D Vitaliano; Jessica M Medina; Richard C Krapf; Heather M Stacy; Marc J Kaufman
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2017-04-20

9.  Amyloid-beta disrupts calcium and redox homeostasis in brain endothelial cells.

Authors:  Ana Catarina R G Fonseca; Paula I Moreira; Catarina R Oliveira; Sandra M Cardoso; Paolo Pinton; Cláudia F Pereira
Journal:  Mol Neurobiol       Date:  2014-05-16       Impact factor: 5.590

Review 10.  Mechanisms of Modulation of Ferroptosis and Its Role in Central Nervous System Diseases.

Authors:  Qingyun Tan; Yuying Fang; Qiong Gu
Journal:  Front Pharmacol       Date:  2021-06-04       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.